Catalyst
Slingshot members are tracking this event:
Catalyst Pharma (CPRX) Agrees with FDA on Special Protocol Assessment (SPA) for Phase 3 Trial Assessing Firdapse in Lambert-Eaton Myasthenic Syndrome (LEMS)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CPRX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 31, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda, Special Protocol Assessment, Spa, Phase 3, Firdapse, Lambert-eaton Myasthenic Syndrome, Lems
